ITIH4 and HIV-1 infection: Interest in antibody functions other than neutralization has recently increased as a result of the RV144 trial, in which a modest reduction in the rate of HIV-1 infection was reported among recipients of a recombinant canarypox vector prime and gp120 protein boost vaccine [51].